Structure TherapeuticsGPCR
GPCR
About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Employees: 148
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
83% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 36
75% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]
12% more capital invested
Capital invested by funds: $2.38B [Q2] → $2.67B (+$294M) [Q3]
12% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $18.6M
0.19% more ownership
Funds ownership: 35.36% [Q2] → 35.55% (+0.19%) [Q3]
4% less funds holding
Funds holding: 166 [Q2] → 159 (-7) [Q3]
20% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 35
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$80
183%
upside
Avg. target
$86
203%
upside
High target
$91
222%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target | 183%upside $80 | Buy Reiterated | 20 Dec 2024 |
JMP Securities Jonathan Wolleben 47% 1-year accuracy 35 / 75 met price target | 222%upside $91 | Market Outperform Reiterated | 18 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
Neutral
CNBC Television
2 weeks ago
Structure CEO on the competitive landscape for oral GLP-1 drugs
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
Neutral
GlobeNewsWire
1 month ago
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.
Neutral
GlobeNewsWire
1 month ago
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity.
Positive
Zacks Investment Research
2 months ago
Best Momentum Stocks to Buy for October 23rd
GPCR, RUSHA and NTRA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 23, 2024.
Positive
Seeking Alpha
2 months ago
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024.
Positive
Zacks Investment Research
2 months ago
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
3 months ago
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer, and will be responsible for clinical development operations, project management, regulatory affairs and quality assurance.
Positive
24/7 Wall Street
3 months ago
Five Top Obesity Stocks to Buy and Hold Long Term
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
Neutral
GlobeNewsWire
3 months ago
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry
Charts implemented using Lightweight Charts™